TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9572097
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of viewing an emotional film and exercise (order conditions 1 + 2)
Study: 9572097
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise and viewing an emotional film (order conditions 2 + 1)
Study: 29454327
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support program (monthly group meetings facilitated by a trained peer leader for 12 months)
Study: 17199929
Drug: Bioadhesive benzalkonium
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bioadhesive benzalkonium chloride (BZK) gel
Study: 17199929
Drug: Nonoxynol-9 (NP-9)
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 (NP-9) gel
Study: 10586392
Drug: Azimilide dihydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide dihydrochloride, intravenous doses of 4.5 to 9 mg/kg over 60 minutes, and 4.5 mg/kg over 15 or 30 minutes
Study: 8835347
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml vaccine, administered three times (first dose, second dose at 1 month, third dose at 6 months)
Study: 8835347
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml vaccine, administered three times (first dose, second dose at 1 month, third dose at 6 months)
Study: 1895263
Drug: Methylprednisolone treatment
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone treatment in glucocorticoid sensitive patients
Study: 1895263
Drug: Control patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients (not specified what treatment they received)
Study: 21062335
Drug: Antibiotics at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics at initial therapy
Study: 21062335
Drug: Antibiotics at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics at re-treatment
Study: 17295333
Drug: Subcutaneous (SQ)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SQ) enoxaparin 1 mg/kg
Study: 17295333
Drug: Supplemental intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental intravenous (IV) enoxaparin (0.3‐0.5 mg/kg)
Study: 17295333
Drug: SQ enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ enoxaparin without IV dosing
Study: 15149341
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (100 mg over 5 minutes)
Study: 11144997
Drug: SCH 48461
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 48461 6.25 to 400 mg
Study: 11144997
Drug: SCH 48461
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 48461 (1 mg to 400 mg)
Study: 11144997
Drug: SCH 48461
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 48461 (25 mg to 400 mg)
Study: 9505058
Drug: ipsapirone 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone 15 mg per day
Study: 9505058
Drug: ipsapirone 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone 22.5 mg per day
Study: 9505058
Drug: lorazepam 3
Normalized name: lorazepam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 3 mg per day
Study: 2100368
Drug: Selective beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective beta-blocker
Study: 7001971
Drug: Ornithine alpha‐ketoglutarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornithine alpha‐ketoglutarate (daily dose containing the same quantity of ornithine)
Study: 25567214
Drug: Gabapentin 500
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 500 mg + Zolpidem 10 mg
Study: 18246854
Drug: Ericksonian therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ericksonian therapy using hypnosis (ET)
Study: 23174499
Drug: Brief dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief dynamic therapy (BDT)
Study: 12884985
Drug: 4-chloro-m-cresol 75
Normalized name: p-Chloro-m-cresol
DrugBank: Chlorocresol (DB16864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-chloro-m-cresol 75 micromol L(‐1)
Study: 9231315
Drug: Methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3 and 0.5/0.6 mg/kg daily for a minimum of 1 week)
Study: 30694338
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy plus bid S. boulardii 250 mg
Study: 30694338
Drug: Standard sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sequential therapy of bid omeprazole 20 mg plus amoxicillin 1 g for 5 days, followed by bid omeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg
Study: 17879541
Drug: SQFZI combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQFZI combined with chemotherapy (docetaxel, flurouracil, calcium folinate)
Study: 17879541
Drug: SQFZI combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQFZI combined with chemotherapy
Study: 17457123
Drug: Microemulsion propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microemulsion propofol (Aquafol; 2 mg/kg bolus followed by variable rate infusion for 60 min)
Study: 17457123
Drug: Lipid emulsion
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid emulsion propofol (Diprivan; 2 mg/kg bolus followed by variable rate infusion for 60 min)
Study: 10789325
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (n = 36) underwent four, monthly 25% drug reduction stages
Study: 10789325
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 20) with no planned drug changes
Study: 10789325
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (n = 36) undergoing drug reduction
Study: 9149200
Drug: ANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP infusion (2, 4, and 6 pmol/kg.min for 15 min each)
Study: 31161361
Drug: Local desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local desmopressin (10 μg) administered as a single puff in each side of the nasal cavity 30 minutes before surgery
Study: 26979520
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice daily in combination with dipyridamole slow-release 200 mg twice daily
Study: 26979520
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice daily alone
Study: 19960983
Drug: Renshen Jianxin
Normalized name: Dianexin
DrugBank: Dianexin (DB15000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renshen Jianxin Capsule (RJC)
Study: 11135086
Drug: L-folinic acid
Normalized name: L-Folinic acid
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-folinic acid (FNA) 20 mg/day
Study: 11135086
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) 15 mg/day
Study: 9853274
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg o.d.
Study: 9853274
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg o.d. + indomethacin 50 mg bid
Study: 9853274
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg o.d. + indomethacin 50 mg bid
Study: 8037389
Drug: Prochlorperazine 25
Normalized name: prochlorperazine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 25 mg rectal suppository
Study: 31852749
Drug: 2×10^6/kg BM-MNC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2×10^6/kg BM-MNC injection
Study: 31852749
Drug: 5×10^6/kg BM-MNC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5×10^6/kg BM-MNC injection
Study: 25408331
Drug: Serelaxin 10
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin 10 µg/kg/day
Study: 25408331
Drug: Serelaxin 30
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin 30 µg/kg/day
Study: 25408331
Drug: Serelaxin 100
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin 100 µg/kg/day
Study: 25408331
Drug: Serelaxin 30
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin 30 µg/kg/day (Caucasian cohort)
Study: 23278466
Drug: Vasoconstrictor (somatostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoconstrictor (somatostatin or terlipressin infusion)
Study: 23278466
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (omeprazole or pantoprazole infusion)
Study: 20541832
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily training plus usual care
Study: 19471252
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) maintenance therapy
Study: 17461851
Drug: TMC114/ritonavir (TMC114/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC114/ritonavir (TMC114/r) 600/100 mg twice a day
Study: 17461851
Drug: Control protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control protease inhibitor (CPI)
Study: 15141519
Drug: Intrapartum antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapartum antibiotic prophylaxis with Penicillin G or Clindamycin for GBS carriers (161 out of 754 newborns, 21.4%)
Study: 1440744
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention (18 therapy appointments over one year, including one home visit)
Study: 3770386
Drug: Viscous lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscous lidocaine gargle (2%) diluted with tap water (39 ml + 15 ml)
Study: 3770386
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (neither viscous lidocaine nor placebo)
Study: 30337746
Drug: Group D1
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D1 (10 mL of 0.375% ropivacaine + dexmedetomidine 0.2 μg/(kg×h))
Study: 30337746
Drug: Group D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group D2 (10 mL of 0.375% ropivacaine + dexmedetomidine 0.7 μg/(kg×h))
Study: 30337746
Drug: Group R
Normalized name: Typhus group rickettsia Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group R (10 mL of 0.375% ropivacaine)
Study: 15781679
Drug: UV facial
Normalized name: ZINC OXIDE 70 g in 1000 g / OCTINOXATE 75 g in 1000 g TOPICAL LOTION [EltaMD UV Facial SPF30 Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV facial photograph and photoaging information plus sunless tanning lotion
Study: 10505829
Drug: Masked review
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Masked review of a complete pediatric ophthalmic exam
Study: 28864226
Drug: CDDP with
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP with Mg (2.5mg/kg CDDP, 40mg/kg MgSO4)
Study: 28864226
Drug: CDDP with
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP with Mg
Study: 23314670
Drug: Bifidobacterium infantis
Normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium infantis natren life start strain super strain (Lifestart 2) (2×10(9) colony‐forming units per capsule) for 3 weeks
Study: 19947443
Drug: Strontium ranelate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strontium ranelate, a first-line agent for the treatment of postmenopausal osteoporosis.
Study: 17123867
Drug: Melatonin (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (intravenous administration)
Study: 15170026
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microg twice a day)
Study: 9433336
Drug: Paroxetine 10
Normalized name: PARoxetine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 10 mg/day
Study: 7663801
Drug: L-NMMA (490
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (490 mg by inhalation)
Study: 7663801
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg orally for 3 days)
Study: 2698244
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg pindolol
Study: 2698244
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg propranolol
Study: 30451047
Drug: Self-administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administration
Study: 27576596
Drug: Buprenorphine mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine mixed with lignocaine 2% with adrenaline 1:80,000 (0.01mg buprenorphine/ml)
Study: 23153715
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation as an add-on therapy for refractory epilepsy
Study: 17103437
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy (1 mg/m²/day) for 2 years
Study: 17103437
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy (1.5 mg/m²/day) for 1 year after 1 year of observation
Study: 17103437
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without GH treatment for 1 year
Study: 3777545
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment (heparin for 21 days followed by antivitamin K drugs for 30 days)
Study: 3777545
Drug: Acute hemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hemodilution with 40,000 daltons molecular weight dextran, haematocrit 0.25-0.30, followed by the same anticoagulant treatment as in group I
Study: 9643595
Drug: No alteration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No alteration of anticoagulant treatment (study group)
Study: 9643595
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment stopped for 2-3 days (control group)
Study: 27890713
Drug: Single IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of 20, 100, or 200 × 10^6 human bone marrow-derived mesenchymal stem cells
Study: 27890713
Drug: Single IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of human mesenchymal stem cells
Study: 21311063
Drug: High-sensitivity C-reactive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity C-reactive protein >3 mg/L
Study: 21311063
Drug: Homocysteine >15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homocysteine >15 umol/L
Study: 17418554
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg twice daily + Montelukast 5mg once daily
Study: 17418554
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg twice daily + Formoterol 9 microg twice daily
Study: 17418554
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg twice daily + Montelukast 5mg once daily (second month)
Study: 17418554
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg twice daily + Formoterol 9 microg twice daily (second month)
Study: 17418554
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg twice daily (first and second month)
Study: 15145911
Drug: Treatment to
Normalized name: Lice Treatment Topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment to below 140/90 mm Hg
Study: 11304898
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 1 mg/kg loading infusion over 30 minutes followed by 1 mg/kg/day continuous i.v. infusion
Study: 9789204
Drug: 0.006 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.006 mg/kg apomorphine
Study: 9789204
Drug: 0.012 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.012 mg/kg apomorphine
Study: 2657045
Drug: Oral ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ritodrine (20 mg every four hours)
Study: 2657045
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline (5 mg every four hours)
Study: 29795365
Drug: Control (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (daily self‐weighing and text messaging feedback)
Study: 19141661
Drug: Monthly home
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly home visits from trained volunteers over a 9‐month period
Study: 16454834
Drug: Peg-interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-interferon alpha-2b (100 microg/wk) + lamivudine (100 mg/day)
Study: 15237079
Drug: Algorithm-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-guided treatment (ALGO)
Study: 10322844
Drug: Fuganlin (FGL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuganlin (FGL) oral liquid
Study: 10322844
Drug: Antipyretic oral
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antipyretic oral liquid (Control)
Study: 6817658
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention (absence of inhaled cromoglycate)
Study: 31702402
Drug: Clonazepam 2
Normalized name: clonazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 2 mg test tablet (Sanofi‐Aventis de Colombia S.A.)
Study: 26342812
Drug: Transurethral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral injection of polyacrylamide hydrogel (Bulkamid) in Group A (previous radiotherapy)
Study: 26342812
Drug: Transurethral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral injection of polyacrylamide hydrogel (Bulkamid) in Group B (no previous radiotherapy)
Study: 11250974
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lefradafiban three times daily
Study: 11250974
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg lefradafiban three times daily
Study: 11250974
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg lefradafiban three times daily
Study: 9827736
Drug: MDI-spacer (salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI-spacer (salbutamol delivered via metered-dose inhaler plus spacer, 2.4 mg/h, 4 puffs at 10-minute intervals for 3 hours)
Study: 9827736
Drug: NEB (nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEB (nebulized salbutamol, 6 mg/h, 1.5 mg at 15-minute intervals for 3 hours)
Study: 10150549
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) with midazolam sedation
Study: 26754759
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of beta-lactam antibiotics
Study: 26754759
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus (IB) dosing of beta-lactam antibiotics
Study: 26754759
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) and Intermittent bolus (IB) dosing
Study: 21913408
Drug: reamberin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: reamberin (800 ml/day for 8 days)
Study: 10780124
Drug: Active Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Nicotine Patch
Study: 8398824
Drug: Serum thymidine
Normalized name: Thymidine
DrugBank: Thymidine (DB04485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum thymidine kinase (STK) < 6 U/l
Study: 8398824
Drug: Serum thymidine
Normalized name: Thymidine
DrugBank: Thymidine (DB04485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum thymidine kinase (STK) > 11 U/l
Study: 8398824
Drug: ABCM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABCM treatment (adriamycin, BCNU, cyclophosphamide and melphalan)
Study: 3095558
Drug: Central venous
Normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central venous parenteral nutrition (TPN)
Study: 24032716
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy exercise program
Study: 21963124
Drug: Vacuum-assisted socket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-assisted socket suspension system (VASS)
Study: 21963124
Drug: Pin lock
Normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pin lock suspension system